Efficacy, safety and cost of new cardiovascular drugs: A survey

Research output: Contribution to journalArticlepeer-review


To assess the type and degree of innovation of the cardiovascular drugs centrally approved in the European Union between 1995 and 2002. Sources of information were the European Public Assessment Reports and the Summaries of Product Characteristics published by the European Medicines Evaluation Agency. The Agency approved 11 active substances belonging to 5 therapeutic classes: anti-hypertensives, anti-arrhythmics, anti-platelets, anti-coagulants and fibrinolytics. Analysis of the documentation on which the marketing authorisation was based shows few elements of innovation. Moreover, the new drugs usually cost more than similar drugs already available. Cardiovascular drugs approved in Europe in the last few years have contributed little to progress in this area. These approvals provide no real advantage to patients and lay an economic burden on society.

Original languageEnglish
Pages (from-to)701-706
Number of pages6
JournalEuropean Journal of Clinical Pharmacology
Issue number8-9
Publication statusPublished - Nov 2003


  • Cardiovascular drugs
  • Drug regulation
  • European market

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Efficacy, safety and cost of new cardiovascular drugs: A survey'. Together they form a unique fingerprint.

Cite this